Nusinersen
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Nusinersen: From Spinal Muscular Atrophy to Tendinopathy
One-Sentence Summary
Nusinersen is an antisense oligonucleotide originally used to treat spinal muscular atrophy (SMA). The TxGNN model predicts it may be effective for tendinopathy, but the prediction score is uninformative (50%) and there are 0 clinical trials and 0 publications supporting this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Spinal muscular atrophy |
| Predicted New Indication | Tendinopathy |
| TxGNN Prediction Score | 50.00% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, nusinersen is an intrathecally administered antisense oligonucleotide that modulates splicing of the SMN2 gene in motor neurons, and its efficacy in spinal muscular atrophy is established.
No mechanistic link to tendinopathy could be identified. Tendinopathy is a primarily peripheral connective tissue disorder with no known SMN-dependent pathology. A TxGNN score of 0.5 carries no discriminating information, so this prediction should be regarded as a model output without biological support.
The other nine top-ranked predictions (CDKL5 disorder, epilepsy of infancy with migrating focal seizures, Rowley-Rosenberg syndrome, myoclonic encephalopathy in non-progressive disorder, febrile seizures plus, ectodermal dysplasia syndrome, ECHS1-related paroxysmal dyskinesia, adolescent/adult-onset epilepsy syndrome, and saccharopinuria) share the same 0.5 score, no clinical trials, and no mechanistic rationale. For several of these (e.g., CDKL5 disorder and KCNT1-related epilepsy), gene-specific antisense oligonucleotides are under investigation, but that would require different, sequence-specific molecules, not nusinersen.
Clinical Trial Evidence
Currently no related clinical trials registered for tendinopathy.
Literature Evidence
Currently no related literature available for tendinopathy.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16751P | SPINRAZA SOLUTION FOR INJECTION 12MG/5ML | Injection, solution | Not stated in the data compiled for this report |
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found, and no contraindication data were available from the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on an uninformative model score (0.5), with no clinical trials, no literature, and no plausible mechanistic link between SMN2 splice modulation in motor neurons and tendinopathy. Route compatibility has not been assessed, and the package insert safety data remain missing.
To proceed, the following is needed:
- Mechanism of action data (MOA) from DrugBank
- Package insert warnings and contraindications from the HSA website
- A documented biological rationale linking SMN2 splicing to tendon pathology
- Preclinical evidence in a tendinopathy model
- Assessment of route compatibility (intrathecal injection versus the needs of a peripheral tendon disorder)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.